General Information

Australian Heavy Rare Earths Producer, Northern Minerals Limited Converts Lind Debt into Equity; Settles R&D Tax Dispute with the ATO

August 27th, 2020

Converts Lind Debt into Equity Australian heavy rare earths producer, Northern Minerals Limited, has issued 66,666,667 shares to a nominee of Lind Global Macro Fund, by converting $1.2 million worth of convertible security into ordinary shares. Resulting from this conversion, there are no amounts outstanding under the replacement convertible security. In accordance with the terms of the funding agreement entered into with Lind in March 2020, Lind has elected to reduce the collateral shareholding from 60,000,000 shares to zero, by […]

Read More

Argent Minerals (ASX:ARD) Announces Details of R&D Tax Dispute Settlement and Progression of Further Claims

August 17th, 2020

Argent Minerals Limited has previously disclosed a liability in the company’s 2019 annual report for “R&D Claims repayable” of approximately $1.4M. This liability was in respect of R&D Tax Offsets for the FY16 and FY17 periods that AusIndustry had found related to ineligible activities. Argent Minerals Limited had, at the time reported that the company remained of the view that its R&D activities were eligible, and intended to pursue a dispute of the adverse finding. In May 2020, the company […]

Read More

Adjustments Required to R&D Claims for JobKeeper Payments – ATO Position Released

July 28th, 2020

As had been anticipated, the ATO will be requiring adjustments to R&D claims that contain salaries reimbursed by the JobKeeper Scheme. Companies lodging FY20 R&D claims who have also received the JobKeeper stimulus must carefully review and adjust R&D claims where necessary. The basis of this need for adjustment is the ATO’s position that companies are not deemed to incur salary expenditure at their own financial risk where such costs are being reimbursed by the Job Keeper Scheme. Draft Taxation […]

Read More

Telix Pharmaceuticals reports receipt of $11.4M Refundable R&D Tax Offset

July 27th, 2020

Melbourne based Telix Pharmaceuticals Ltd has reported during the week receipt of a $11.4M Refundable R&D Tax Offset in respect of activity conducted during the YE 31 December 2019. This would be one of the largest single year Refundable offset receipts in the history of the R&D Tax Incentive, and infers an R&D Expenditure of approximately $26M AUD. The underlying activity relates to development of diagnostic and therapeutic products using molecularly targeted radiation. Receipt of a tax offset of this magnitude reduces […]

Read More

Categories

Archives

    Email this job